GYRO:NASDAQGyrodyne , LLC Analysis
Data as of 2026-04-07 - not real-time
$8.13
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Gyrodyne, LLC is trading well below its short‑ and long‑term moving averages, with a bearish MACD and an RSI deep in oversold territory, suggesting continued downside pressure. The company’s fundamentals are weak – revenue is shrinking, margins are negative, cash flow is negative and debt levels are high – while the price‑to‑earnings multiple sits far above the industry average, indicating an overvalued equity on an earnings basis despite a low price‑to‑book ratio. Volume has been falling and 30‑day volatility exceeds 20%, further amplifying the risk of sharp moves. Recent insider selling adds a negative sentiment cue.
Given the combination of technical weakness, deteriorating financial health, high debt load, and thin trading liquidity, the outlook remains challenging across all horizons, and any upside would likely require a material operational turnaround or successful entitlement of its real‑estate assets.
Given the combination of technical weakness, deteriorating financial health, high debt load, and thin trading liquidity, the outlook remains challenging across all horizons, and any upside would likely require a material operational turnaround or successful entitlement of its real‑estate assets.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish technical indicators (price below SMAs, negative MACD)
- Decreasing volume and high short‑term volatility
- Negative earnings and cash flow with elevated debt
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Continued earnings deficits and zero free cash flow
- High PE relative to industry peers
- Insider selling signaling lack of confidence
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Uncertain ability to monetize undeveloped real‑estate assets
- Persistent high leverage and low ROE/ROA
- Thin market cap and liquidity constraints limiting upside
Key Metrics & Analysis
Financial Health
Revenue Growth-1.80%
Profit Margin-137.05%
P/E Ratio47.8
Debt/Equity69.24
P/B Ratio0.2
Op. Cash Flow$-3440937
Industry P/E31.9
Technical Analysis
TrendBearish
RSI24.6
Support$7.83
Resistance$9.00
MA 20$8.40
MA 50$8.73
MA 200$9.34
MACDBearish
VolumeDecreasing
Fear & Greed Index77.54
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta0.11
Volatility20.25%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.